Innovent's Taletrectinib Study Results Revealed at ASCO Annual Meeting
Saturday, 1 June 2024, 21:12
Innovent Publishes Data from Phase 2 TRUST-I Study
In a groundbreaking update, Innovent has shared key insights from the Phase 2 TRUST-I study, highlighting the efficacy of Taletrectinib in targeting ROS1-positive cancers.
Pivotal Findings Revealed at ASCO Annual Meeting
The data, presented at the 2024 ASCO Annual Meeting, underscores the potential of Taletrectinib as a cutting-edge ROS1 inhibitor.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.